| Literature DB >> 29724076 |
Moussa Yabré1,2, Ludivine Ferey3, Issa Touridomon Somé4, Karen Gaudin5.
Abstract
The greening of analytical methods has gained increasing interest in the field of pharmaceutical analysis to reduce environmental impacts and improve the health safety of analysts. Reversed-phase high-performance liquid chromatography (RP-HPLC) is the most widely used analytical technique involved in pharmaceutical drug development and manufacturing, such as the quality control of bulk drugs and pharmaceutical formulations, as well as the analysis of drugs in biological samples. However, RP-HPLC methods commonly use large amounts of organic solvents and generate high quantities of waste to be disposed, leading to some issues in terms of ecological impact and operator safety. In this context, greening HPLC methods is becoming highly desirable. One strategy to reduce the impact of hazardous solvents is to replace classically used organic solvents (i.e., acetonitrile and methanol) with greener ones. So far, ethanol has been the most often used alternative organic solvent. Others strategies have followed, such as the use of totally aqueous mobile phases, micellar liquid chromatography, and ionic liquids. These approaches have been well developed, as they do not require equipment investments and are rather economical. This review describes and critically discusses the recent advances in greening RP-HPLC methods dedicated to pharmaceutical analysis based on the use of alternative solvents.Entities:
Keywords: alternative solvents; ethanol; green liquid chromatography; ionic liquids; micellar liquid chromatography; pharmaceutical analysis; reversed-phase chromatography
Mesh:
Substances:
Year: 2018 PMID: 29724076 PMCID: PMC6100308 DOI: 10.3390/molecules23051065
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Examples of pharmaceutical analysis in RP-HPLC using ethanol-based mobile phases.
| Compounds | Matrix | Column | Mobile Phase | Flow Rate (mL/min) | Temperature (°C) | Detection | Ref |
|---|---|---|---|---|---|---|---|
| Prednisolone | Tablets | Phenomenex C18 (150 × 4.6 mm, 5 μm) | EtOH/water (30:70, | 0.8 | 50 | UV (254 nm) | [ |
| Diltiazem | Topical formulations | C18 column (250 × 4.6 mm, 5 μm) | EtOH/H3PO4 (pH 2.5) (35:65, | 2 | 50 | UV (240 nm) | [ |
| Permethrin isomers | Pharmaceutical formulations (cream) | C18 column (150 × 4.6 mm, 5 μm) | EtOH/H3PO4 (pH 3.0) (67:33, | 1 | 30 | UV (215 nm) | [ |
| Ampicilline sodium | Powder for injection solution | Zorbax C18 (150 × 4.6 mm, 5 μm) | EtOH/water (40:60, | 0.5 | 25 | UV (210 nm) | [ |
| Statins: pravastatin; fluvastatin; atorvastatin | Pharmaceutical hydro-alcoholic solutions | ODS-AQ YMC C18 (50 × 4.6 mm, 3 µm) | EtOH/25 mM formic acid (pH 2.5) (50:50, | 1.0 | 40 | UV (238 nm) | [ |
| Daptomicin | Lyophilized powder | Zorbax C18 (150 × 4.6 mm, 5 μm) | EtOH/water (55:45, | 0.6 | 25 | UV (221 nm) | [ |
| Dextromethorphan and its impurities | Pharmaceutical products | Acquity BEH C18 (50 × 2.1 mm, 1.7 μm) | Gradient elution of EtOH/10 mM ammonium formate buffer (pH 4.7) | 0.23 | 38 | UV (280 nm) | [ |
| Mebeverine hydrochloride/sulpiride | Coformulated pharmaceuticals | Zorbax SBC18 (75 × 4.6 mm, 3.5 µm) | EtOH/water (94.5:5.5, | 0.8 | room temperature | UV (220 nm) | [ |
| Chlorphenoxamine hydrochloride/caffeine/chlorotheophylline | Coformulated pharmaceuticals | Polaris SI (50 × 4.6 mm, 3 µm) | EtOH (100%) | 0.4 | room temperature | UV (220.4 nm, 270.4 nm, and 276.4 nm) | [ |
| Clidinium bromide/chlordiazepoxide hydrochloride; phenobarbitone/pipenzolate bromide | Coformulated pharmaceuticals | Zorbax SBC18 (75 × 4.6 mm, 3.5 µm) | EtOH/water (50:50, | 0.5 | room temperature | UV (210 nm and 220 nm) | [ |
| Telmisartan; hydrochlorothiazide; amlodipine besylate | Tablets | Intersil ODS-3 C18 (250 × 4.6 mm, 5 μm) | EtOH/20 mM phosphate buffer (pH 7) (70:30, | 0.7 | 25 | UV (240 nm) | [ |
| Phenylephrine; Paracetamol; Guaifenesin | Tablets | Onyx Monolithic C18 (100 × 4.6 mm) | Gradient elution of EtOH/phosphate buffer (pH 7) | 2 | Room temperature | UV (220 nm) | [ |
| Cefepime hydrochloride | Lyophilized powder for solution for injection | Luna C18 (250 × 4.6 mm, 5 μm) | EtOH/water (55:45, | 0.5 | UV (258 nm) | [ | |
| Lansoprazole enantiomers | Stainless-steel Chiralpak IC-3 (100 × 4.6 mm) | EtOH/water (50:50, | 1.0 | 40 | UV (210 nm and 280 nm) | [ | |
| Dapsone | Pharmaceutical preparations | C18 | EtOH/formic acid (pH 3) (10:90, | UV detection | [ | ||
| Caffeic acid | Pharmaceutical products | RP18 XDB Waters (250 × 4.6 mm, 5 μm) | EtOH/acetic acid (pH 2.5) (40:60, | 0.7 | 25 | UV (325 nm) | [ |
| Ertapenem sodium | Powder for injection solution | Zorbax Bonus-RP (150 × 4.6 mm, 5 μm) | EtOH/0.1% formic acid (20:80, | 1.0 | UV (297 nm) | [ | |
| Rifaximin | Tablets | Eclipse Plus C18 (150 × 4.6 mm) | EtOH/0.1% glacial acetic acid (52:48, | UV (290 nm) | [ | ||
| 16 active pharmaceutical ingredients | Xbridge BEH Shield RP18 (50 × 4.6 mm, 2.5 µm) | Gradient elution of EtOH/20 mM acetate buffer (pH 4.85) | 0.8 | 33.7 | UV (210 nm) | [ | |
| Quetiapine | Rat plasma | Acquity BEH C18 (50 × 2.1 mm, 1.7 μm) | EtOH/water/formic acid (80:20:0.1, | 0.3 | 40 | MS/MS detection | [ |
| Capecitabine | Human plasma | C18 RP column | EtOH/formic acid (pH 3) (55:45, | 1.0 | 50 | UV (310 nm) | [ |
Figure 1Comparison of Van Deemter curves of atorvastatin obtained using ethanol or acetonitrile in mobile phases. Xbridge BEH Shield RP18 (50 × 4.6 mm i.d., 2.5 µm); Chromolith (SpeedROD RP18, 50 × 4.6 mm i.d., 2 µm); YMC-ODS-AQ (50 × 4.6 mm i.d., 3 µm); Hypersil GOLD (50 × 4.6 mm i.d., 1.9 µm). Isoeluotropic mobile phases: EtOH/formic acid (pH 2.5, 25 mM) in proportions 40/60 (v/v) for YMC column; 38/62 (v/v) for Xbridge and Hypersil columns; and 35/65 (v/v) for Chromolith column. HETP: height equivalent to a theoretical plate. Similar to Reference [42].
Figure 2Reversed-phase high-performance liquid chromatography (RP-HPLC) chromatogram of a mixture of dextromethorphan (DXM), its impurities, and excipients. Acquity BEH C18 column (50 × 2.1 mm i.d, 1.7 µm). Gradient elution of ethanol (slope of 3.1%/min) with 10 mM ammonium formate adjusted at pH 4.7 with formic acid. Flow rate: 0.23 mL/min. Temperature: 38.0 °C. Detection at 280 nm. Similar to Reference [44].
Figure 3Separation of 16 active pharmaceutical ingredients. Xbridge BEH Shield RP18 column (50 × 4.6 mm i.d., 2.5 µm). Gradient elution of ethanol from 5% to 80% (slope of 2.57%/min) with acetate buffer 20 mM at pH 4.85. Flow rate: 0.8 mL/min. Temperature: 33.7 °C. Detection at 210 nm. Peak identification: 1 = paracetamol; 2 = doxylamine; 3 = ondansetron; 4 = melatonin; 5 = quinine; 6 = metopimazine; 7 = domperidone; 8 = pravastatin; 9 = ketoprofen; 10 = rosuvastatin; 11 = midazolam; 12 = diclofenac; 13 = atorvastatin; 14 = fluvastatin; 15 = artemether; and 16 = simvastatin. Similar to Reference [54].
Some recent applications of MLC in pharmaceutical analysis.
| Compounds | Matrix | Column | Mobile Phase | Temperature (°C) | Detection | Ref |
|---|---|---|---|---|---|---|
| Seven tricyclic antidepressants | Pharmaceutical formulations | Zorbax C18 | 0.02 M Brij-35 with citric buffer, pH 3.0 | 25 | UV (254 nm) | [ |
| Six β-blockers | Zorbax Eclipse C18 | 0.02 M Brij-35 and 0.15 M SDS with 0.01 M NaH2PO4 and HCl, pH 3.0 | 25 | UV (225 nm) | [ | |
| Seven tricyclic antidepressants | Zorbax Eclipse C18 | 0.02 M Brij-35 with 0.01 M NaH2PO4 and HCl, pH 3.0 | 25 | UV (254 nm) | [ | |
| Free ampicillin | Standard solutions of human serum albumin | RP-8 endcapped column | 0.06 M CTAB + 20% ACN ( | 20 | UV (254 nm) | [ |
| Nelfinavir mesylate | Tablets | Licrosphere c18 | 0.5 M Tween-20 + 2% | 25 | UV (249 nm) | [ |
| Piroxicam, tenoxicam, and lornoxicam | Gel and suppositories | C8 column | 0.15 M SDS + 10% | Time-programmed UV detection | [ | |
| Citalopram, paroxetine, and fluoxetine | Plasma and urine | Kromasil C18 | 0.075 M SDS + 6% | 25 | Fluorescence detection program | [ |
| Sildenafil citrate | Oral suspensions and tablets | ACE 5 C18–AR column | 0.0082 M SDS with acetate buffer, pH 4.0 | room temperature | UV (298 nm) | [ |
| Abacavir, lamivudine, and raltegravir | Human plasma | Kromasil C18 | 0.05 M SDS, pH 7.0 | room temperature | UV (260 nm) | [ |
| Nicotine | Pharmaceutical formulations and biological fluid | Kromasil C18 | 0.15 M SDS + 6% | Electrochemical detector (0.8 V) UV (259 nm) | [ | |
| Tamoxifen | Plasma of breast cancer patients | Kromasil 5 C18 | 0.15 M SDS + 7% | 40 | Fluorescence (260 nm/380 nm) | [ |
| Penicillin antibiotics (amoxicillin, ampicillin, cloxacillin, and dicloxacillin) | Pharmaceutical formulations and physiological fluids (urine) | Zorbax C18 | 0.11 M SDS + 6% | 25 | UV (210 nm) | [ |
| Tamoxifen and endoxifen | Plasma samples from breast cancer patients | Kromasil C18 | 0.15 M SDS + 7% | 40 | Fluorescence (260 nm/380 nm) | [ |
| Morphine, codeine, papaverine, and noscapine | Pharmaceutical solution for injection | Kromasil C18 | 0.10 M SDS + 5% | 40 | UV (280 nm) | [ |
| Derivatives of zidovudine | Simulated gastric and intestinal fluids | Phenomenex Synergi Fusion-RP 80 | 0.05 M SDS + 1% | 30 | UV (267 nm) | [ |
| Lamivudine and its carbonate derivatives | Simulated gastric and intestinal fluids | Kromasil C18 | 0.15 M SDS + 4% | 30 | UV (272 nm) | [ |
| Flavoxate hcl | Tablets | BDS Hypersil phenyl | 0.15 M SDS + 15% | UV (325 nm) | [ | |
| Diltiazem hydrochloride, metoprolol tartrate, and isosorbide mononitrate | Human serum | Pinnacle II Cyano column | 0.0415 M SDS + 10% | 40 | UV (225 nm) | [ |
| Tizoxanide | Human urine and plasma | Chromolith® C18 | 0.1 M SDS + 8% | 25 | UV (240 nm) | [ |
| β-blockers (acebutolol, atenolol, carteolol, labetolol, metoprolol, and propranolol , celiprolol, and oxprenolol) | Urine samples | Zorbax Eclipse XDB-C8 and Zorbax Eclipse XDB-C18 | Gradient mode: 0.10 M SDS + | 25 | UV (225 nm) | [ |
| Felodipine | Tablets and human plasma | Shim-pack CLC-C18 | 0.085 M SDS + 6.5% | 30 | Fluorescence (240 nm/440 nm) | [ |
| Darunavir, ritonavir, emtricitabine, and tenofovir | Human plasma | Kromasil C18 column | 0.06 M SDS + 2.5% | room temperature | UV (214 nm) | [ |
| Ascorbic acid, pseudoephedrine hydrochloride, and ibuprofen | Tablets | ODS C18 stainless steel | 0.03 M SDS + 8% 1-propanol ( | UV (260 nm) | [ | |
| Ofloxacin and flavoxate | Pharmaceutical formulations | BDS Hypersil phenyl | 0.15 M SDS + 15% | UV (325 nm) and fluorescence (290 nm/485 nm) | [ | |
| Tamoxifen and its main metabolites | Plasma samples from breast cancer patients | C18 column | 0.08 M SDS + 4.5% | 40 | Fluorescence (260 nm/380 nm) | [ |
| Enalapril maleate, lisinopril dihydrate, benazepril hydrochloride, and hydrochloro-thiazide | Tablets | C18 silica column | 0.012 M SDS + 10% | UV (210 nm) | [ | |
| Esomeprazole, leflunomide, and ibuprofen | Human plasma and tablets | Shim-pack VP-ODS stainless steel column | 0.1 M SDS + 10% | UV (285 nm) | [ | |
| Axitinib, lapatinib, and afatinib | Plasma | Kromasil C18 column | 0.07 M SDS + 6.0% | UV (260 nm) | [ |
ACN, acetonitrile; CTAB, cetyltrimethylammonium bromide; SDS, sodium dodecyl sulfate; TEA, triethylamine.